Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Top Page
TG Therapeutics
(NASDAQ:TGTX)
Select Model
Select Model
Rating:65Neutral
Price Target:
$37.00
▲(21.95% Upside)
TG Therapeutics' strong earnings call and valuation are significant positives, reflecting confidence in future growth and an undervalued stock. However, technical indicators suggest bearish momentum, and financial performance shows risks in cash flow management and debt reliance.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful product adoption and market expansion, enhancing long-term financial stability.
Clinical Developments
Rapid enrollment in clinical trials suggests robust demand and potential for future product approvals, strengthening competitive position.
Market Expansion
Expanding market presence with new prescribers boosts revenue potential and solidifies the company's position in the MS treatment market.
Negative Factors
Cash Flow Challenges
Negative cash flows indicate potential liquidity issues, which could hinder investment in R&D and long-term growth initiatives.
Increased Operating Expenses
Rising operating expenses may pressure margins and profitability, impacting the company's ability to sustain long-term growth.
Limited Ex-U.S. Sales
Limited international sales growth restricts global market potential, potentially capping future revenue streams and diversification.
TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.67B
Dividend YieldN/A
Average Volume (3M)1.37M
Price to Earnings (P/E)10.9
Beta (1Y)0.57
Revenue Growth100.88%
EPS GrowthN/A
CountryUS
Employees352
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.43
Shares Outstanding158,759,450
10 Day Avg. Volume1,378,181
30 Day Avg. Volume1,365,715
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue10.22
Enterprise Value/Gross Profit11.97
Enterprise Value/Ebitda47.15
Forecast
1Y Price Target
$43.50Price Target Upside43.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)1.83
Revenue Forecast (FY)$901.46M
TG Therapeutics Business Overview & Revenue Model
Company DescriptionTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
How the Company Makes MoneyTG Therapeutics generates revenue primarily through the sale of its therapeutics once they are approved by regulatory agencies and brought to market. The company also engages in partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of products developed through these partnerships. Additionally, TG Therapeutics may receive funding from grants or government programs aimed at supporting the development of innovative therapies. As the company progresses in clinical trials and gains regulatory approvals, its revenue potential increases significantly through market access and sales of its product portfolio.
TG Therapeutics Earnings Call Summary
Earnings Call Date:Nov 03, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance, positive developments in clinical trials, and an increase in market presence and revenue guidance. However, there were challenges with increased operating expenses and limited ex-U.S. sales growth. Overall, the highlights significantly outweigh the lowlights.Q3-2025 Updates
Positive Updates
Strong Financial Performance
Total revenue reached $161.7 million, an increase of 93% compared to Q3 '24 and 15% over Q2 '25. U.S. BRIUMVI net sales in Q3 totaled approximately $153 million, exceeding internal targets and Street expectations.
Positive Clinical Developments
Enrollment for the ENHANCE study completed quickly, indicating strong interest. The Phase III subcutaneous ublituximab study is on track, with potential approval and launch in 2028.
Share Repurchase Program
Completed initial $100 million share repurchase program, buying back 3.5 million shares. An additional $100 million program authorized.
Sustained Demand and Market Expansion
The CD20 class now represents nearly $10 billion in annual U.S. MS sales. BRIUMVI's market presence expanded with new prescribers and accounts.
Raised Full-Year Revenue Guidance
Full year 2025 U.S. BRIUMVI net revenue guidance increased to approximately $585 million.
Negative Updates
Increased Operating Expenses
Total operating expenses increased compared to the second quarter of '25, primarily due to investment in R&D for subcutaneous BRIUMVI and higher SG&A spend.
Limited Ex-U.S. Sales
Ex-U.S. sales of $6.4 million, showing limited expansion outside the U.S. market.
Company Guidance
In the recent earnings call, TG Therapeutics provided comprehensive guidance on its financial outlook and product development. The company reported strong third-quarter performance, with U.S. net sales for BRIUMVI, their flagship product for relapsing multiple sclerosis (MS), totaling approximately $153 million. This exceeded both internal targets and market expectations, driven by sustained physician engagement and increasing patient awareness. TG Therapeutics raised its full-year 2025 U.S. BRIUMVI net revenue guidance to approximately $585 million, reflecting strong demand trends. They also discussed ongoing pivotal studies, including the ENHANCE trial aiming for a simplified dosing schedule by 2027 and the Phase III subcutaneous ublituximab study, with potential approval in 2028. The company completed a $100 million share repurchase program and announced another $100 million authorization. Despite market temptations, TG Therapeutics remains financially disciplined, focusing on long-term growth and maintaining operational profitability, with a reported GAAP net income of $390.9 million for the quarter.TG Therapeutics Financial Statement Overview
Summary
TG Therapeutics shows strong revenue growth and improving profitability, with a significant increase in net profit margins. However, challenges in cash flow management and reliance on debt financing pose risks.Income Statement
TG Therapeutics has shown impressive revenue growth, particularly in the TTM period with a 17.52% increase. The company maintains strong gross profit margins above 86%, indicating efficient cost management. Net profit margins have improved significantly, reaching 13.31% in the TTM, reflecting enhanced profitability. However, the company has a history of negative margins, which poses a risk if growth slows.Balance Sheet
The balance sheet shows a moderate debt-to-equity ratio of 0.92 in the TTM, indicating manageable leverage. Return on equity has improved to 26.05%, showcasing effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing, which could be risky in volatile markets.Cash Flow
Cash flow analysis reveals challenges, with negative operating and free cash flows in the TTM. The free cash flow to net income ratio is slightly above 1, indicating that cash flow generation is not yet robust. The negative growth in free cash flow highlights the need for improved cash management strategies.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 531.90M | 329.00M | 233.66M | 2.79M | 6.69M | 152.00K |
| Gross Profit | 453.87M | 290.52M | 219.11M | 2.52M | 5.90M | 152.00K |
| EBITDA | 115.24M | 49.90M | 26.10M | -213.11M | -341.97M | -272.68M |
| Net Income | 447.47M | 23.38M | 12.67M | -223.81M | -348.10M | -279.38M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 577.69M | 329.59M | 193.57M | 379.63M | 625.64M |
| Cash, Cash Equivalents and Short-Term Investments | 131.58M | 311.00M | 217.51M | 161.68M | 314.76M | 605.43M |
| Total Debt | 253.72M | 253.72M | 110.80M | 83.06M | 79.05M | 41.98M |
| Total Liabilities | 417.81M | 355.33M | 169.09M | 134.99M | 142.48M | 106.29M |
| Stockholders Equity | 607.22M | 222.36M | 160.50M | 58.59M | 237.15M | 519.35M |
Cash Flow | ||||||
| Free Cash Flow | -70.24M | -40.56M | -31.41M | -176.18M | -296.04M | -214.86M |
| Operating Cash Flow | -70.07M | -40.52M | -31.41M | -176.17M | -295.63M | -214.51M |
| Investing Cash Flow | 45.23M | -1.04M | -50.65M | -20.01M | -332.00K | -24.51M |
| Financing Cash Flow | -96.86M | 128.53M | 72.70M | -391.00K | 41.42M | 679.83M |
TG Therapeutics Technical Analysis
Negative
30.34
Price Trends
31.54
Negative
32.19
Negative
34.36
Negative
Market Momentum
-0.51
Positive
47.18
Neutral
44.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 30.34 is below the 20-day moving average (MA) of 30.57, below the 50-day MA of 31.54, and below the 200-day MA of 34.36, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 47.18 is Neutral, neither overbought nor oversold. The STOCH value of 44.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.
TG Therapeutics Risk Analysis
TG Therapeutics disclosed 75 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TG Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $4.67B | 10.92 | 111.96% | ― | 100.88% | ― | |
64 Neutral | $10.15B | -27.90 | -9.06% | ― | 4.14% | -179.96% | |
59 Neutral | $6.63B | -32.74 | -240.36% | ― | 54.92% | 28.47% | |
56 Neutral | $13.20B | -48.60 | -39.99% | ― | 20.39% | 34.00% | |
54 Neutral | $7.07B | -20.09 | -38.79% | ― | ― | -52.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $8.66B | ― | -275.50% | ― | 65.83% | 28.50% |
* Healthcare Sector Average
TGTX
TG Therapeutics
30.50
1.62
5.61%
IONS
Ionis Pharmaceuticals
81.54
48.08
143.69%
JAZZ
Jazz Pharmaceuticals
160.25
38.84
31.99%
AXSM
Axsome Therapeutics
167.55
87.50
109.31%
RYTM
Rhythm Pharmaceuticals
97.46
41.29
73.51%
NUVL
Nuvalent
102.67
26.06
34.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.